CD19-Targeting CAR T-Cell Therapy for Antisynthetase Syndrome

JAMA. 2023 Jun 27;329(24):2130-2131. doi: 10.1001/jama.2023.7240.

Authors

Ingrid E Lundberg^{1

2

3}, Angeles S Galindo-Feria^{1

2

3}, Begum Horuluoglu^{1

2

3}

Affiliations

¹ Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
² Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden.
³ Department of Gastro, Dermatology, and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.

PMID: 37367988
DOI: 10.1001/jama.2023.7240

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antigens, CD19*
Humans
Immunotherapy, Adoptive*
Myositis* / immunology
Myositis* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Antigens, CD19
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen

Supplementary concepts

Antisynthetase syndrome